Table 1: Summary of nonengraftment cellular therapy results.

Author Number of patients Conditioning regimen Number of CD3 cells infused Response rate (CR/PR) Colvin et al. [16] 19 patients (AML/NHL only) 100 cGy TBI 1 × 106–2 × 108/kg 37% (26%/11%) Guo et al. [17] 30 patients (AML) Mitoxantrone 8–10 mg/m2 (3 days) and cytarabine 150 mg/m2 (7 days) 0.5–2.6 × 108/kg 80% (80%/NR) *O’Donnell et al. [18] 4 patients (ALL, MDS) Fludarabine 30 mg/m2, 200 cGy TBI, Post transplant ± Pretransplant cyclophosphamide 2.6–3.8 × 107/kg 75% (75%/0%) *Dey et al. [19] 22 patients (NHL, HL, Multiple Myeloma) Cyclophosphamide 50 mg/kg (3-4 days), ATG 15–30 mg/kg (3-4 days), and anti-CD 2 monoclonal antibody 1 × 107–2.98 × 108/kg 41% (18%/22%)

*Only patients who did not engraft in this study are included in the results. AML= acute myeloid leukemia, NHL= non-Hodgkins lymphoma, MDS= myelodysplastic syndrome, ALL= acute lymphocytic leukemia, HL= Hodgkins lymphoma.